Researchers at Queen Mary University of London’s Precision Healthcare Research Institute (PHURI) and the Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin have identified the genetic causes of Raynaud’s phenomenon. Their findings, published today (12 October) in Nature Communications, could lead to the first effective treatments for people with Raynaud’s.
Epilepsy drug may alleviate joint degeneration associated with osteoarthritis
A new study in Nature described Nav1.7 as a key regulatory molecule in cartilage cells and reported the effectiveness of Nav1.7 blockade in reducing pain
January 5, 2024